Balancing Consumer Protection and Innovation in FMCG Health Claims
Fast-moving consumer goods (FMCG) regulation plays a crucial role in safeguarding consumers from misleading health claims. In Great Britain, the regulatory framework ensures that only authorised nutrition and health claims, as listed in the Great Britain nutrition and health claims register, are permitted on packaging, websites, advertisements, and social media. This system helps prevent exaggerated or unsubstantiated promises, especially those suggesting food products can prevent, treat, or cure diseases, which fall under medicines regulation. However, while this framework is necessary for consumer protection, it also presents hurdles for evidence-led innovation, especially in functional foods and drinks.
At The Turmeric Co., some of the most extensive discussions have revolved around the precise wording used to describe products. Questions like whether the term “supports” can be used, or if words like “recovery” require additional context, reveal the complexity of regulatory language. This challenge arises despite significant investments in formulation, manufacturing, and scientific research, demonstrating that explaining innovative products clearly can be as demanding as developing them.
The Innovation-Regulation Gap
The experience of The Turmeric Co. illustrates a broader tension between innovation and regulation. Initially, the company’s turmeric shots were created to aid recovery from injury. When manufacturers found fresh ingredients difficult to process at scale, the company developed its own capabilities, highlighting how innovation often outpaces existing systems. This same tension exists in regulatory processes, which can struggle to keep pace with emerging scientific evidence and novel product formulations.
For instance, customer reviews, a critical source of genuine consumer feedback, become problematic from a regulatory perspective. Although a customer’s personal account may reflect real benefits, brands cannot use these testimonials in advertising if they contain health claims not authorised under the existing framework. The Advertising Standards Authority (ASA) clearly states that testimonials are subject to the same advertising rules and that a testimonial alone does not constitute scientific evidence. This approach, while protecting consumers, can limit how brands communicate authentic experiences, impacting commercial trust and customer decision-making.
Challenges of Product Labelling and Evidence Submission
Labeling also poses a significant challenge, particularly for small-format functional drinks. Legally required information such as ingredients, allergens, nutrition details, storage, and manufacturer information must fit within limited packaging space. To address this, many brands are incorporating digital layers, such as QR codes, to provide in-depth information on sourcing, formulation, and scientific research—an effective way to complement physical labels without overwhelming the consumer.
Beyond packaging, the process for gaining approval for new health claims is lengthy and complex. Applicants must submit a comprehensive scientific dossier and await evaluation by the UK Nutrition and Health Claims Committee, which has a five-month window to issue an opinion. This is followed by a public comment period and then a two-month decision phase. Additional queries can further prolong the process. While multinational companies often have the resources to navigate this lengthy procedure, smaller or growing FMCG businesses may find the costs and timelines prohibitive, affecting their ability to invest in research and innovate effectively.
Moreover, the current authorised wording tends to focus on familiar nutrients like vitamins and minerals, which can lead to different products sounding similar even when they contain unique functional ingredients. This restricts brands’ ability to communicate their true innovations and risks homogenising the market.
Modernising the Health-Claims Framework
The path forward involves modernising the regulatory process while maintaining rigorous evidential standards. Regulators could enhance transparency by offering structured scientific guidance before applications are submitted, clarifying expectations around study design, evidence quality, and product information requirements. Establishing transparent target timelines and more frequent updates to the nutrition and health claims register would also improve responsiveness.
Better coordination between assessments related to health claims, novel foods, and borderline medicines is another area ripe for improvement. This would reduce duplication and confusion, streamlining the route to market without compromising consumer safety.
At the same time, brands bear responsibility for integrating claims strategy, advertising, and substantiation early in the product development process. Ensuring that every health claim is backed by credible evidence and communicated without exaggeration is essential for building consumer trust and maintaining regulatory compliance.
Conclusion: Building a Trustworthy and Innovative FMCG Sector
Great Britain has the opportunity to create a health-claims framework where robust regulation and pioneering innovation mutually reinforce each other. By providing brands with clearer, more accessible pathways to communicate credible evidence, the UK can empower responsible FMCG companies to compete effectively on the quality and authenticity of their products. Ultimately, consumers stand to benefit the most when innovation thrives within a trustworthy and transparent regulatory environment.
For further insights on this evolving landscape, read more here.
